Multiple Sclerosis and Related Disorders Journal

Improved are the backbone of being able to accurately and cohesively diagnoses persons with . Find out more about the experience with new guidelines in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00700-8/fulltext

Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis Clinical practice guidelines for multiple sclerosis (MS) have been developed since the first disease-modifying drugs were licensed in the nineties and have been updated ever since (Rae-Grand et al., 2018, Montalban et al., 2018, Chan et al., 2014, Hemmer et al., 2021). However, despite the high qual...

in is generally considered safe although regional differences in care are likely to be predictive of associated outcomes. Find out more about the experience with pregnancy in MS in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00658-1/fulltext

Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative disease. MS represents a leading cause of non traumatic disability in young people. This disease predominantly affects young women. Significant proportion of them become ill prior to manage their maternal wishes. Current treatm...

and awareness are highly specialized processing skills of the human brain. Very little is known about the impact of these structures in persons with . Find out more in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00689-1/fulltext

Spatial navigation performance in people with multiple sclerosis-a large-scale online study Multiple sclerosis (MS) is a progressive disease of the central nervous system characterized by white matter lesions, axonal damage, and cerebral atrophy (Huijbregts et al., 2006). It is estimated that 2.3 million people around the world live with MS, with the average age at diagnosis being 30 yea...

We continue to search for effective in persons with although neurofilament light seems to be promising. Find out more about the factors that contribute to its rise and fall in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00676-3/fulltext

Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: an observational study Body Mass Index

has been linked with in persons with . Find out more about the link between this DMT and molloscum contagiosum in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00685-4/fulltext

Molluscum contagiosum in the setting of Fingolimod: The experience at one institution Fingolimod treatment has been associated with opportunistic infections, most notably PML and cryptococcal meningitis. There are rare reports of other infections like molluscum contagiosum which are typically associated with impaired cellular immunity as seen in AIDS. Upon review of our multiple scle...

Although we feared that could trigger relapses in some individuals with neuroimmune diseases at the start of the , this was hypothetical. Find out more about the actual risk of relapse after COVID19 vaccination in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00690-8/fulltext

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related pandemic have posed relevant challenges in the management of patients with demyelinating CNS disorders. In particular, the urgent need for mass vaccination has raised the question whether SARS-CoV-2 vaccines may i...

Therapeutic advances in have rapidly changed the way patients are treated in the last half decade. Find out more about the experience with treatment in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00675-1/fulltext

Response to treatment in NMOSD: the Australasian experience Neuromyelitis optica spectrum disorder (NMOSD) is a potentially devastating disease of the central nervous system (CNS) (Jarius et al., 2012). The current diagnostic criteria for NMOSD (Wingerchuk et al., 2015) recognise a collection of six types of clinical presentation commonly associated with...

Can be triggered by ? Very rarely but find out more in this unique case report in MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00680-5/fulltext

Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review Neuromyelitis optica spectrum disorders (NMOSD) is a relapsing inflammatory central nervous system (CNS) disorder commonly presenting with optic neuritis (ON) and acute transverse myelitis (TM). The pathogenesis involves the interplay between aquaporin 4 (AQP4) antibody, complements, and antibody-me...

Is it ever reasonable to stop in persons with ? Find out more about the differences in stopping at young versus older age in individuals with stable disease in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00673-8/fulltext

Discontinuation of Disease Modifying Therapies is Associated with Disability Progression Regardless of Prior Stable Disease and Age Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) with a well-recognized neurodegenerative component. The successful advent of potent anti-inflammatory disease modifying therapies (DMT) has contributed to a significant demographic shift. (Wallin et al., 20...

What drives the decision to escalate therapies in persons with ? Find out more about the rationale that and specialists use to make these critical decisions in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00671-4/fulltext

Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study The landscape of multiple sclerosis (MS) management is constantly evolving as new disease modifying therapies (DMTs) become available (Cree et al., 2019; Rotstein and Montalban, 2019). However, the growing spectrum of drug safety profiles adds a layer of uncertainty to the already difficult ther...

Neurosarcoidosis is a rare disorder of the CNS without clear clinical or outcome measures. Find out more about this unique condition in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00670-2/fulltext

Clinical Perspective on Clinical Outcome Assessments in Neurosarcoidosis : There are no validated clinical outcome assessments (COAs) used in neurosarcoidosis.

The decision to get in women with is complex. Find out more about the role of therapeutic inertia and its impact on choices in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00656-8/fulltext

Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists Multiple sclerosis (MS) is an immune-mediated neurological disorder of the central nervous system and affects at least 2.5 million individuals worldwide. MS is one of the most common causes of neurological disability in young adults. Overall, three out of four people with MS (pwMS) are women, and mo...

Merry Christmas and Happy Holidays from the team at MSARD. We will be on a brief holiday break until the beginning of the new year but look forward to highlighting new advances in the field in 2022.

in persons with can be significant. Find out more about the impacts on job productivity in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00665-9/fulltext

Measuring productivity loss in early relapsing-remitting multiple sclerosis Multiple sclerosis is one of the most common causes of neurological disability in young adults with major consequences for their autonomy and capacity to maintain employment.

As neurologists, the focus during the has been preventing infection although a silent of , , and has emerged in persons with neuroimmune disorders. Find out more in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00637-4/fulltext

A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic Coronavirus outbreak (SARS-CoV-2) emerged in Wuhan province of China towards the end of 2019 and it was announced as a pandemic on March 11, 2020, when the first case was reported in Turkey (Acar et al., 2020; WHO, 2019). The spread of the coronavirus influenced the daily routines, social and econ...

Statin therapy has made the rounds in multiple autoimmune diseases in an attempt to augment . Find out about the potential for these compounds in persons with in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00662-3/fulltext

The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: a systematic review and meta-analysis annualized relapse rate

in persons with and other neuroinflammatory disorders is controversial in the setting of the potential to trigger relapse. Find out more about vaccination in persons with NMOSD in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00661-1/fulltext

Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy? Currently, the pandemic of COVID-19 has impacted our lives in every aspect. Meanwhile, with preventive medicine development, vaccine hesitancy has gradually increased and become an emerging clinical problem (MacDonald and Hesitancy, 2015). Although healthy individuals can be infected, certain grou...

Researchers focus on white matter in but often this can be interpreted as normal by radiologists. Find out more about advanced neuroimaging techniques that can interrogate "normal" appearing white matter in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00663-5/fulltext

Quantification of normal-appearing white matter damage in early relapse-onset multiple sclerosis through neurite orientation dispersion and density imaging Neurodegeneration represents a major component of multiple sclerosis (MS) pathology and contributes to motor and cognitive disability accrual. (Filippi et al., 2018); Filippi et al., 2020) Axonal and neuronal damage could be the consequence of demyelination with loss of homeostatic and trophic s...

is a newer DMT in the space. Find out more about safety, tolerability and efficacy in this upcoming article in MSARD:

https://www.msard-journal.com/article/S2211-0348(21)00652-0/fulltext

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning (Jongen, 2017; Oreja-Guevara, 2015; Orme et al., 2007; Pashazadeh Kan et al., 2020; Epub ahead of print...

As a new variant heats up, what do we know about T-cell mediated responses to vaccines in persons with ? Find out more in this upcomming article in MSARD!

https://www.msard-journal.com/article/S2211-0348(21)00649-0/fulltext

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab Clinicians caring for individuals with multiple sclerosis (MS) have faced significant challenges during the coronavirus (COVID-19) pandemic. Disease modifying therapies (DMTs), and specifically, anti-CD20 therapies, can increase susceptibility to infection and impair the response to vaccines. (Hause...

Advanced techniques are becoming more and more able to predict in persons with . Find out more about prediction modeling in persons with MS in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00256-X/fulltext

Prediction of unenhanced lesion evolution in multiple sclerosis using radiomics-based models: a machine learning approach Multiple sclerosis is a chronic inflammatory demyelinating neurodegenerative disease of the central nervous system (CNS). The most obvious hallmark of MS pathology is the focal demyelination plaques, which harbour variable degrees of inflammation, demyelination, axonal injury, and reactive gliosis s...

Many of the used by rheumatologists have been linked to and . Find out more in this recent editorial in MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00324-2/fulltext

Can rheumatologists stop causing demyelinating disease? Multiple sclerosis (MS) is the major demyelinating disease of the central nervous system (CNS) that affects about 2–3 million people worldwide (Dobson and Giovannoni, 2019). This is typically characterised by relapsing neurological attacks associated with peripheral inflammatory, mononuclear cel...

Early exposure has been hypothesized to be beneficial in preventing although little is known about the of this hypothesis. Find out more from an upcoming systematic review in this issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00313-8/fulltext

Childhood pet ownership and multiple sclerosis: A systematic review and meta-analysis Multiple sclerosis (MS) is one of the most common chronic neurological diseases affecting young adults (Browne, Chandraratna et al. 2014). It is thought to be caused by combination of environmental and genetic factors (Olsson, Barcellos et al. 2017). Genetic influences have primarily focussed ...

is critically important for individuals with disorders such as . Find out more about towards vaccination against in in this issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00312-6/fulltext

Attitudes toward vaccination in patients with multiple sclerosis: A report from Iran The recent pandemic by the novel coronavirus (SARS CoV-2) has brought up many psychosocial changes among different societies worldwide. Patients with chronic diseases, especially those on immune-modulatory and immune suppressor drugs need special attention. Multiple sclerosis (MS) is a chronic autoi...

It's now easier to send Multiple Sclerosis and Related Disorders Journal a message.

is an interesting and emerging concept on brain function in persons with . Find out more regarding this unique assessment modality in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00423-5/fulltext

Theory of mind and its neuroanatomical correlates in people with multiple sclerosis Social cognition comprises various psychological processes that enable individuals to take advantage of being part of social group (Frith, 2008). Since social cognition has a critical role in social relationships in humans, it has led to interest and has been studied intensively in recent decades. ...

The of ( ) has undergone dramatic changes over the last decade since the identification of against . Find out more about the historical role of ( ) in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00448-X/fulltext

Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis Neuromyelitis optica spectrum disorders (NMOSD) is an immune-mediated inflammatory central never system (CNS) disorder with severe attacks of optic neuritis and transverse myelitis. Historically, NMOSD was considered a variant of MS, but since the discovery of serum antibodies against aquaporin-4 (A...

and remedies in are highly desirable for many patients given the of traditional . Find out more about the role of in this systematic review in this issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00426-0/fulltext

High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials Multiple sclerosis (MS) is a chronic, demyelinating condition affecting mainly the white matter of the central nervous system (CNS) (Filippi et al., 2018). The reduction of inflammatory activity in MS is achieved by current disease-modifying therapies (DMTs) via cellular immunomodulation of the ad...

is an established in persons with . formulations exists but not in all places across the globe. Find out more about this alternative therapeutic delivery in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00446-6/fulltext

429 Internal Server Error

are an established criteria for persons with . Find out more about the continued utility of this historical biomarker in this upcoming issue of MSARD.

https://www.msard-journal.com/article/S2211-0348(21)00487-9/fulltext

Reinforcing the evidence of oligoclonal bands as a prognostic factor in patients with Multiple sclerosis The prognostic value of oligoclonal bands in the cerebrospinal fluid of Multiple Sclerosis (MS) patients is controversial. While several studies have demonstrated a worse disease course in OCB positive patients, others did not reproduce these findings. We evaluated the prognostic significance of OCB...